{
    "Trade/Device Name(s)": [
        "cobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 Systems"
    ],
    "Submitter Information": "Roche Molecular Systems, Inc.",
    "510(k) Number": "K213804",
    "Predicate Device Reference 510(k) Number(s)": [
        "K211079"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QQX"
    ],
    "Summary Letter Date": "December 3, 2021",
    "Summary Letter Received Date": "December 6, 2021",
    "Submission Date": "December 2, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device to detect and identify nucleic acid targets in respiratory specimens from microbial agents that cause the SARS-CoV-2 respiratory infection and other microbial agents when in a multi-target test"
    ],
    "Analyte Class(es)": [
        "virology",
        "genetic molecular",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA",
        "pan-Sarbecovirus RNA"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Universal Transport Media (UTM-RT)",
        "cobas PCR Media",
        "0.9% physiological saline"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas 6800 Systems",
        "cobas 8800 Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time RT-PCR",
        "Nucleic acid extraction",
        "Fluorescent probe detection (TaqMan/FRET)"
    ],
    "Methodologies": [
        "Real-time PCR",
        "RT-PCR",
        "Molecular amplification and detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Automated system",
        "Reagent",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for cobas SARS-CoV-2 Qualitative real-time RT-PCR test for detection of SARS-CoV-2 RNA in respiratory specimens on cobas 6800/8800 Systems",
    "Indications for Use Summary": "Intended for qualitative detection of nucleic acids from SARS-CoV-2 in nasal and nasopharyngeal specimens from symptomatic individuals suspected of COVID-19 by healthcare provider; results are for detection of SARS-CoV-2 RNA and must be used in conjunction with clinical assessment and public health guidelines",
    "fda_folder": "Microbiology"
}